The legend for Figure 1 on page 7156 was inadvertently transposed with the legend for Figure 2 on page 7157. Additionally, in the figure key of Panel D in Figure 1, “LET” should read “IgG.” The corrected Figure 1 and Figure 2 are shown below.
Figure 1.
Outcomes in CMV+ treated with letermovir. (A) Cumulative incidence in csCMVi landmarked from the date of transplantation in patients with seropositive CMV treated with letermovir and not treated with letermovir. CMV reactivation was not seen in patients without CMV in this cohort. (B-D) Cumulative incidence of csCMVi in patients treated with letermovir ≥14 weeks (n = 80) landmarked from the time of letermovir withdrawal: (B) entire cohort; (C) patients are grouped based on time of discontinuation of letermovir; and (D) patients are group based on IgG level before letermovir discontinuation (<650 vs ≥650 mg/dl).
View largeDownload PPT

Outcomes in CMV+ treated with letermovir. (A) Cumulative incidence in csCMVi landmarked from the date of transplantation in patients with seropositive CMV treated with letermovir and not treated with letermovir. CMV reactivation was not seen in patients without CMV in this cohort. (B-D) Cumulative incidence of csCMVi in patients treated with letermovir ≥14 weeks (n = 80) landmarked from the time of letermovir withdrawal: (B) entire cohort; (C) patients are grouped based on time of discontinuation of letermovir; and (D) patients are group based on IgG level before letermovir discontinuation (<650 vs ≥650 mg/dl).

Figure 1.
Outcomes in CMV+ treated with letermovir. (A) Cumulative incidence in csCMVi landmarked from the date of transplantation in patients with seropositive CMV treated with letermovir and not treated with letermovir. CMV reactivation was not seen in patients without CMV in this cohort. (B-D) Cumulative incidence of csCMVi in patients treated with letermovir ≥14 weeks (n = 80) landmarked from the time of letermovir withdrawal: (B) entire cohort; (C) patients are grouped based on time of discontinuation of letermovir; and (D) patients are group based on IgG level before letermovir discontinuation (<650 vs ≥650 mg/dl).
View largeDownload PPT

Outcomes in CMV+ treated with letermovir. (A) Cumulative incidence in csCMVi landmarked from the date of transplantation in patients with seropositive CMV treated with letermovir and not treated with letermovir. CMV reactivation was not seen in patients without CMV in this cohort. (B-D) Cumulative incidence of csCMVi in patients treated with letermovir ≥14 weeks (n = 80) landmarked from the time of letermovir withdrawal: (B) entire cohort; (C) patients are grouped based on time of discontinuation of letermovir; and (D) patients are group based on IgG level before letermovir discontinuation (<650 vs ≥650 mg/dl).

Close modal
FIgure 2.
Risk of CMV reactivation based on clinical and laboratory parameters. (A) Major lymphocyte subsets in patients treated with letermovir after allo-HCT: ALC, CD3+CD4+CD8− T cells (CD4), CD3+CD4−CD8+ T-cells (CD8), CD3−CD56+ NK cells, CD3−CD19+ B cells (CD19) are shown. There were no statistically significant differences between patients who experienced or those who did not experience csCMVi. (B) Pre-letermovir discontinuation IgG levels. ∗P < .05; ∗∗P < .005 (Wilcoxon rank-sum test).
View largeDownload PPT

Risk of CMV reactivation based on clinical and laboratory parameters. (A) Major lymphocyte subsets in patients treated with letermovir after allo-HCT: ALC, CD3+CD4+CD8− T cells (CD4), CD3+CD4−CD8+ T-cells (CD8), CD3−CD56+ NK cells, CD3−CD19+ B cells (CD19) are shown. There were no statistically significant differences between patients who experienced or those who did not experience csCMVi. (B) Pre-letermovir discontinuation IgG levels. ∗P < .05; ∗∗P < .005 (Wilcoxon rank-sum test).

FIgure 2.
Risk of CMV reactivation based on clinical and laboratory parameters. (A) Major lymphocyte subsets in patients treated with letermovir after allo-HCT: ALC, CD3+CD4+CD8− T cells (CD4), CD3+CD4−CD8+ T-cells (CD8), CD3−CD56+ NK cells, CD3−CD19+ B cells (CD19) are shown. There were no statistically significant differences between patients who experienced or those who did not experience csCMVi. (B) Pre-letermovir discontinuation IgG levels. ∗P < .05; ∗∗P < .005 (Wilcoxon rank-sum test).
View largeDownload PPT

Risk of CMV reactivation based on clinical and laboratory parameters. (A) Major lymphocyte subsets in patients treated with letermovir after allo-HCT: ALC, CD3+CD4+CD8− T cells (CD4), CD3+CD4−CD8+ T-cells (CD8), CD3−CD56+ NK cells, CD3−CD19+ B cells (CD19) are shown. There were no statistically significant differences between patients who experienced or those who did not experience csCMVi. (B) Pre-letermovir discontinuation IgG levels. ∗P < .05; ∗∗P < .005 (Wilcoxon rank-sum test).

Close modal
© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
2024